Skip to content

Transcriptomic landscape of granulosa cells for women with advanced maternal age with different ovarian reserves

Transcriptomic landscape of granulosa cells for women with advanced maternal age with different ovarian reserves

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065720
Enrollment
Unknown
Registered
2022-11-14
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

Case series:N/A

Sponsors

Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to 42 Years

Inclusion criteria

Inclusion criteria: 1. Aged 35-42 year, women undergoing IVF-ET and using antagonist regimen; 2. Expected NOR (normal responder) : 7 <= basal sinus follicle number (AFC) <= 15; 1.2 ng/ml <= anti-muller in vitro hormone (AMH) <= 4 ng/ml; Basal follicle stimulating hormone (FSH) level < 10 mIU/ml; 3. No previous history of IVF cycle cancellation with low or high ovarian response; Expected DOR (normal responder): basal sinus follicle number (AFC) <=5; Anti-muller test-tube hormone (AMH) <= 1.2ng /ml.

Exclusion criteria

Exclusion criteria: 1. BMI>=28kg/m^2; 2. IVF/ICSI attempts >= 3 times; 3. Patients with a history of recurrent abortion and repeated implantation failure; 4. Abnormal reproductive system development, male and female chromosome karyotype has one abnormal; 5. Endocrine disorders (diabetes mellitus, hyperprolactinemia, thyroid insufficiency, congenital adrenal hyperplasia, Cushing's syndrome or polycystic ovary syndrome); 6. Untreated moderate to severe endometriosis, submucosal fibroids, multiple endometrial polyps, pelvic inflammatory disease, uterine malformations, Asherman syndrome, and hydrosalpinx; 7. Currently participating in another interventional clinical trial or other in vitro fertilization contraindications.

Design outcomes

Primary

MeasureTime frame
Number of MII oocyte;Transcriptomic landscape;

Secondary

MeasureTime frame
High quality embryo rate;Two-pronuclear fertilization rate;Number of oocytes;Incidence of ovarian hyperstimulation syndrome;Available quality embryo number;

Countries

China

Contacts

Public ContactGuo Ying

The First Clinical Medical College of Shandong University of Chinese Medicine/Affiliated Hospital of Shandong University of Chinese Medicine

js1228gigi@126.com+86 13864138647

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026